SkyePharma subsidiary Jago has been granted its first product approval,in Switzerland, for Madopar-DR, a new controlled-release formulation of levodopa and benzerazide for the treatment of Parkinson's disease. The product was developed with Roche, which already markets an immediate-release formulation of the drug, and will be launched later this year.
Madopar-DR is based on Jago's binary Geomatrix technology, which allows two drugs to be delivered simultaneously from a single multilayer tablet with different release profiles.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze